Authors
Latest:
PrimeMD, a Pain Reporting Smartphone Application for Patients Undergoing Head and Neck RadiationA feasibility study of a smartphone application that patients undergoing radiation therapy for head and neck cancer can use to regularly report mucositis symptoms.
Latest:
MD Anderson Launches Institute for Cell Therapy Discovery & Innovation to Deliver Transformational New TherapiesThe institute builds upon institutional expertise to develop and advance impactful cell therapies for cancer, autoimmune conditions and infections.
Latest:
20 Best Health 2.0 Tools for Physicians and PatientsThe premise of Health 2.0 rests on one simple idea: whatever your healthcare question or concern may be, there is a potential community of likeminded individuals out there who are ready and willing to share.
Latest:
Value and Market Access Considerations Often Missing From Trial DesignHaving an evidence package at launch that satisfies payers’ value criteria will increase the likelihood that payers will reimburse the drug at a desirable price and enable patient access to innovative treatments.
Latest:
Dr. Moran on Techniques to Decrease Toxicities With Radiation in Breast CancerMeena Savur Moran, MD, radiation oncologist, professor, Therapeutic Radiology, director, Breast Cancer Radiotherapy Program, Yale Cancer Center, discusses some of the techniques that oncologists can use to decrease the toxicities associated with radiation therapy when treating patients with breast cancer.
Latest:
Dr. Daly on Clinical Trials With Radiation Therapy in Lung CancerMegan E. Daly, MD, assistant professor of radiation oncology, UC Davis Cancer Center, discusses upcoming clinical trials involving radiation therapy for the treatment of lung cancer.
Latest:
Immunotherapy Continues to Advance in Head and Neck CancerAn early-stage trial is examining the addition of nivolumab to a cetuximab regimen in head and neck squamous cell carcinoma.
Latest:
Clinical Benefits With Neratinib in HER2+ Early Breast CancerVijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.
Latest:
Genetic Counseling for Patients with Non-Clear Cell RCCThe panel closes their discussion with a look at the standards for genetic counseling for patients with non-clear cell RCC.
Latest:
The Longstanding Quest for a Better Endocrine Therapy Continues High-Dose Fulvestrant: Have We Found Its Effective Dose, Combination, Setting, or Sequence?Although several endocrine therapies are available today, the authors of this commentary contend that the quest for a better tamoxifen is ongoing.
Latest:
Dr. Hashmi on Immunotherapy in Prostate CancerMehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses the use of immunotherapy in the treatment of patients with prostate cancer.
Latest:
Fixed-Duration Therapy Struggles to Find Footing Across Tumor TypesFixed-duration systemic therapies have gained some traction in hematologic malignancies, where advances in drug development and sequencing strategies have afforded investigators the opportunity to conduct trials.
Latest:
Novel Therapies for T315I-Mutant Chronic Myeloid LeukemiaAbelson tyrosine kinase (ABL1) is a nonreceptor tyrosine kinase involved in cell growth and proliferation.
Latest:
Dr. Thomas Discusses the Potential Utility for PF-03446962 in HCCMelanie B. Thomas, MD, medical oncologist, associate director for clinical trials, Hollings Cancer Center, Medical University of South Carolina, discusses the potential utility for the monoclonal antibody PF-03446962 in hepatocellular carcinoma (HCC).
Latest:
Dr. Majure on Unmet Needs for Patients With TNBCMelanie C. Majure, MD, assistant clinical professor in the Division of Hematology/Oncology and breast oncologist, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses unmet needs for patients with triple-negative breast cancer (TNBC).
Latest:
Dr. Royce on Progress Being Made in HER2+ Positive Breast CancerMelanie E. Royce, MD, PhD, co-director, Protocol Review and Monitoring System, member, Women’s Cancers Research Program, associate professor of Medicine, University of New Mexico Comprehensive Cancer Center, discusses some of the progress currently being made in the field of HER2-positive breast cancer.
Latest:
Health-Related Quality of Life (HRQoL) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated With Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) vs. VRd Alone: Results From the IMROZ StudyDr. Dimopoulos presents the results from the IMROZ study, discussing the impact of isatuximab combined with bortezomib, lenalidomide, and dexamethasone on health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma compared to VRd alone.
Latest:
Dr. Dimopoulos Reflects on Ibrutinib Plus Rituximab in Waldenstrom MacroglobulinemiaMeletios Dimopoulos, MD, professor and chairman, Department of Clinical Therapeutics at the University of Athens School of Medicine, Athens, Greece, discusses the impact of the results from the iNNOVATE study of ibrutinib (Imbruvica) plus rituximab (Rituxan) in patients with Waldenström macroglobulinemia.
Latest:
Melinda Irwin on Impact of Exercise on Survivors' Quality of LifeMelinda Liggett Irwin, PhD, MPH, associate professor of epidemiology (chronic diseases), Yale School of Public Health, co-program leader, Cancer Prevention and Control Research Program, Yale Cancer Center, discusses the impact of the LIVESTRONG at the YMCA Program on survivors' fitness, physical activity, and quality of life.
Latest:
Dr. Wilson on Choosing Between BRAF/MEK Therapies for Patients With MelanomaMelissa A. Wilson, MD, PhD, an assistant professor of medicine at Perlmutter Cancer Center at NYU Langone Medical Center, discusses how physicians select between the 2 BRAF/MEK inhibitor combination regimens for their patients with melanoma.
Latest:
The Heart of Collaboration: Oncologists and Nurses Working TogetherThe culture of the nurse-physician relationship has changed dramatically over the past years and is one of the most important drivers of a healthy work environment
Latest:
Dr. Burgess on Pembrolizumab in SarcomaIn the phase II SARC028 trial, single-agent pembrolizumab (Keytruda) demonstrated antitumor activity in patients with advanced soft tissue and bone sarcomas.
Latest:
Dr. Hardesty on Bevacizumab/PARP Inhibitor Combination in Ovarian CancerMelissa Hardesty, MD, gynecologic oncologist, Alaska Women’s Cancer Center, discusses the safety and efficacy of the bevacizumab/PARP inhibitor combination in ovarian cancer.
Latest:
Treatment Strategies for NSCLC With Concomitant KRAS and p53 MutationsBefore closing out their discussion on IO therapy in non–small cell lung cancer, Melissa Johnson, MD, and Joshua Sabari, MD, identify treatment strategies in the setting of concomitant KRAS/p53 mutation.
Latest:
Dr. Accordino on Utility of Liquid Biopsies in Breast CancerMelissa K. Accordino, MD, MS, discusses the utility of liquid biopsies in breast cancer.
Latest:
Future Treatment Approaches for Patients With GliomaMelissa L. Bondy, PhD, MS, Duncan Cancer Center-Bondy Cancer Prevention and Population Sciences, Baylor College of Medicine, discusses future treatment approaches for patients with glioma.
Latest:
Targeted Therapies and Biomarkers for SCLC: What’s Next on the HorizonPanelists discuss how emerging targeted and biomarker-directed therapies are poised to transform the treatment landscape for both limited-stage and extensive-stage small cell lung cancer, highlighting the potential for improved patient outcomes through personalized approaches.
Latest:
New Frontier for Genomics: Radiotherapy in Early Breast CancerBy individualizing risk of locoregional recurrence and radiosensitivity with molecular subtyping/genomic classifiers, it is hoped that use and/or extent of adjuvant radiation therapy could be tailored in early-stage breast cancer.
